INEOS Family Office

INEOS Family Office is the private investment arm tied to the INEOS chemicals group, a roughly $30 billion enterprise managing private wealth with increasing strategic exposure to high-impact life sciences. Based in London, the office deploys patient capital into biotech, deep tech, and pharma/therapeutics opportunities where industrial chemistry, manufacturing scale, or long-horizon scientific bets align with the broader INEOS worldview. As a family office rather than a fund, decisions are concentrated and timelines are flexible, but the bar for scientific and commercial seriousness is high.

The office writes growth-stage checks of $25M and above, focused on Series B, Series C, and later rounds where capital efficiency is proven and scaling capital is what is needed. Geographic scope is global, with a UK and European tilt and selective US participation. They typically co-invest alongside specialist healthcare funds rather than leading complex syndicates.

Founders should expect family-office decision dynamics: fewer formal gates, more principal-level conversations, and a need to articulate strategic relevance rather than pure financial return. Limited public information exists on specific portfolio names, so warm introductions through advisors or co-investors are essentially required. Approach with a fully baked round and clear use of proceeds.